Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| KARYOPHARM THERAP (NASDAQ: KPTI) | Delayed: 0.42 +0.06 (16.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.36 | 52 Week High | $19.41 | |||
| Open | $0.36 | 52 Week Low | $4.83 | |||
| Day High | $0.44 | P/E | N/A | |||
| Day Low | $0.36 | EPS | $-2.74 | |||
| Volume | 1,608,932 | |||||
